Real-world applications of tumor mutation burden (TMB) analysis using ctDNA and FFPE samples in various cancer types of Turkish population
Abstract
Tumor mutation burden (TMB) has become one of the most popular approaches in the last decade as a molecular genetic testing strategy for cancer therapeutics that represents the somatic variations per Mbase in coding regions of the genome and which can be performed via comprehensive genomic profiling (CGP) by next generation sequencing (NGS). TMB is most commonly used to stratify the patients for immunotherapy as well as the actionable variant detection for possible other therapeutics. In this context, within this study, we share our results of the TMB score distribution of cancer patients together with distinctive diagnoses and specimens. The study was conducted from a total of 278 samples. One hundred seventy six (176) of them were formalin-fixed paraffin-embedded (FFPE) tissue samples and 102 liquid biopsy samples. Samples were sequenced using a multi-gene NGS panel consisting of 486 cancer-related genes (Illumina-NextSeq500/550). Bioinformatics analyzes were performed using an optimized in-house bioinformatics pipeline. As a result, the studies of 91.7% (n=255) among all samples were successfully performed in which total of 21 different cancer types were included. The lung cancer group was the most frequent (n=43 patients), followed by 31 colorectal cancer and 22 ovarian cancer patients. The classification of TMB scoring was very high (>50), high (20-50), moderate (5-20) and low (<5). The shared data of this study represents a cancer genome atlas-like data set for TMBs of Turkish cancer patients in relation to various cancer types and specimens in comparison with The Cancer Genome Atlas (TCGA) data.
References
Boga, I., Sonmezler, O., & Bisgin, A. (2020). Clinical Validation of a Novel GeneReader Next Generation Sequencing System for Tumor Specific Mutations and Bioinformatics Variant Analysis. Clin Lab., 66(11). https://doi.org/10.7754/Clin.Lab.2020.200123
Chalmers, Z.R., Connelly, C.F., Fabrizio, D., Gay, L., Ali, S.M., Ennis, R. (2017). Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Medicine, 9(1): 34. https://doi.org/10.1186/s13073-017-0424-2
Lawlor, R.T., Mattiolo, P., Mafficini, A., Hong, S.M., Piredda, M.L., & Taormina, S.V. (2021). Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Pancreatic Cancer: Systematic Review and Still-Open Questions. Cancers, 13(13). https://doi.org/10.3390/cancers13133119
McGrail, D.J., Pilié, P.G., Rashid, N.U., Voorwerk, L., Slagter, M., Kok, M. (2022). Validation of cancer-type-dependent benefit from immune checkpoint blockade in TMB-H tumors identified by the FoundationOne CDx assay. Annals of Oncology, 33(11), 1204-1206. https://doi.org/10.1016/j.annonc.2022.07.009
Sonmezler, O., Boga, I., & Bisgin, A. (2020). Integration of Liquid Biopsies into Clinical Laboratory Applications via NGS in Cancer Diagnostics. Clin. Lab., 66(5). https://doi.org/10.7754/Clin.Lab.2019.190836
Strickler, J.H., Hanks, B.A., & Khasraw, M. (2021). Tumor Mutational Burden as a Predictor of Immunotherapy Response: Is More Always Better? Clinical cancer research: an official journal of the American Association for Cancer Research, 27(5), 1236-1241. https://doi.org/10.1158/1078-0432.CCR-20-3054
Copyright (c) 2022 International Academic Publishing House (IAPH)
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
